BAY1841788 (ODM-201)

DRUG2 trials

Sponsors

Bayer

Conditions

Biological AvailabilityDrug InteractionHealthy VolunteersPharmacokinetics

Phase 1

Drug-drug Interaction Study Using Rosuvastatin as a Breast Cancer Resistant Protein (Efflux Transporter), Organic Anion-transporting Polypeptide (OATP)1B1, and OATP1B3 (Uptake Transporters) Probe Substrate

CompletedNCT02671097

BayerDrug Interaction, Healthy Volunteers, Pharmacokinetics

Start: 2016-02-29End: 2016-08-31Updated: 2016-09-08

Drug-drug Interaction (DDI) Study to Assess ODM-201 as a Victim of CYP3A4 Inhibition or Induction

CompletedNCT03048110

BayerBiological Availability

Start: 2017-02-15End: 2017-07-19Updated: 2018-07-30

Related Papers

Clinical Pharmacokinetics of the Androgen Receptor Inhibitor Darolutamide in Healthy Subjects and Patients with Hepatic or Renal Impairment

Clinical Pharmacokinetics2021-12-0613 citations